Serum IL-6 and CRP Levels in Melanoma Patients
Author Information
Author(s): E. Tartour, T. Dorval, V. Mosseri, L. Deneux, C. Mathiot, H. Brailly, F. Montero, I. Joyeux, P. Pouillart, W.H. Fridman
Primary Institution: Institut Curie
Hypothesis
High serum IL-6 and CRP levels are associated with resistance to IL-2 therapy and poor survival in melanoma patients.
Conclusion
High serum IL-6 and CRP levels could serve as prognostic factors for melanoma patients undergoing IL-2 therapy.
Supporting Evidence
- 26.6% of patients had elevated serum IL-6 levels.
- 46% of patients had elevated CRP levels.
- Only 1 out of 13 patients with high CRP responded to IL-2 therapy.
- None of the 8 patients with elevated IL-6 levels responded to IL-2.
- Patients with high IL-6 levels had a median survival of 3 months.
Takeaway
This study found that melanoma patients with high levels of certain proteins in their blood are less likely to respond to a specific treatment and tend to live shorter lives.
Methodology
Serum IL-6 and CRP levels were measured in melanoma patients before IL-2 therapy, and their clinical responses were analyzed.
Limitations
The small sample size may limit the statistical power of the findings.
Participant Demographics
{"age":{"median":46,"range":"20-69"},"gender_ratio":"1.5 male to female","prognostic_groups":{"Mla":24,"Mlb":6}}
Statistical Information
P-Value
p=0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website